NCT07143955 is a NA clinical trial of Structured Dietary Intervention in Hepatocellular Carcinoma (HCC), sponsored by The First Hospital of Hebei Medical University.

Who is sponsoring NCT07143955?

NCT07143955 is sponsored by The First Hospital of Hebei Medical University.

What drugs are being tested in NCT07143955?

Interventions in NCT07143955: Structured Dietary Intervention, Routine Dietary Care.

What condition does NCT07143955 study?

NCT07143955 studies Hepatocellular Carcinoma (HCC).

Is NCT07143955 still recruiting?

NCT07143955 is currently completed. Last updated 27 August 2025.

Last reviewed 2025-08-27 · How we verify

NCT07143955

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dietary Intervention and Gut Microbiota in Hepatocellular Carcinoma (HCC)

Completed NA Last updated 27 August 2025

What this trial tests

NA trial testing Structured Dietary Intervention in Hepatocellular Carcinoma (HCC) in 100 participants. Completed in 30 September 2023.

Timeline

1 May 2022

Primary endpoint
30 September 2023

30 September 2023

Quick facts

Lead sponsor	The First Hospital of Hebei Medical University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	100
Start date	1 May 2022
Primary completion	30 September 2023
Estimated completion	30 September 2023
Sites	1 location across China

Drugs / interventions tested

Structured Dietary Intervention
Routine Dietary Care

Conditions studied

Hepatocellular Carcinoma (HCC) — all drugs for Hepatocellular Carcinoma (HCC) →

Sponsor

The First Hospital of Hebei Medical University

Who can join

Adults 18 to 80, any sex, with Hepatocellular Carcinoma (HCC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective, randomized controlled trial investigates the efficacy of a targeted dietary intervention in patients with hepatocellular carcinoma (HCC). The study aims to compare a structured diet including probiotics and prebiotics against routine dietary care. The primary goal is to assess the impact on clinical outcomes (survival), gut microbiota composition, systemic lipid metabolism, and anti-tumor immune responses, to determine if this intervention can serve as an effective adjunctive therapy for HCC.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Dietary intervention reshapes gut microbiota and lipid metabolism to enhance anti-tumor immunity and prognosis in hepatocellular carcinoma: a randomized controlled trial.
Shen X, Zhao D, Wang F, Li X, et al · · 2026 · PMID 41491437 · DOI 10.1186/s12885-025-15325-z

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma (HCC)

Currently open trials in the same condition.

NCT07070076 — A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Ther · NA · recruiting
NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
NCT07490262 — A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular · Phase 2, PHASE3 · recruiting
NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting

Other The First Hospital of Hebei Medical University trials

Trials by the same sponsor.

NCT07467603 — ED50 of Remimazolam for Anesthesia Induction in Frail Elderly Patients · NA · completed
NCT07243444 — Home-Based Versus Center-Based Cardiac Rehabilitation After CABG Surgery · NA · completed
NCT07047534 — EEG-Triggered rTMS and Group Therapy for Adolescents With Depression and Self-Harm · NA · completed
NCT07232693 — Telerehabilitation vs. Center-Based Rehab for Psychological Well-being After CABG · NA · completed
NCT06344390 — Effect of Pentoxifylline on Cognitive Impairment After Ischemic Stroke · Phase 1, PHASE2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07143955 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Hospital of Hebei Medical University
Last refreshed: 27 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07143955.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing